Cohera Medical (United States)

Recent papers from Cohera Medical (United States)

1. Integration of an artificial intelligence-based autism diagnostic into the ECHO Autism Primary Care Early Diagnostic workflow: results of a prospective observational study (Preprint)JMIR Formative Research · 2025
2. An analysis of the real world performance of an artificial intelligence based autism diagnosticScientific Reports · 2025
3. Association between Targeted Therapy and Survival in Patients with AMLBlood · 2024
4. Economics and Equity of Large Language Models: Healthcare Perspective (Preprint)Journal of Medical Internet Research · 2024
5. Promises, Pitfalls, and Clinical Applications of Artificial Intelligence in PediatricsJournal of Medical Internet Research · 2024
6. Optimizing a de novo artificial intelligence-based medical device under a predetermined change control plan: Improved ability to detect or rule out pediatric autismIntelligence-Based Medicine · 2023
7. Autism Spectrum Disorder: The New Asthma?Clinical Pediatrics · 2022
8. An Introduction to Artificial Intelligence in Developmental and Behavioral PediatricsJournal of Developmental & Behavioral Pediatrics · 2022
9. Feasibility and Impact of Integrating an Artificial Intelligence–Based Diagnosis Aid for Autism Into the Extension for Community Health Outcomes Autism Primary Care Model: Protocol for a Prospective Observational StudyJMIR Research Protocols · 2022
10. Evaluation of an artificial intelligence-based medical device for diagnosis of autism spectrum disordernpj Digital Medicine · 2022
11. Evaluation of transfection efficacy, biodistribution, and toxicity of branched amphiphilic peptide capsules (BAPCs) associated with mRNABiomaterials Science · 2022
12. Racial, Ethnic, and Sociodemographic Disparities in Diagnosis of Children with Autism Spectrum DisorderJournal of Developmental & Behavioral Pediatrics · 2021
13. Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial2021
14. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients.2020
15. Hydroxychloroquine, nitazoxanide and ivermectin have similar effects in early COVID-19: a head-to-head comparison of the Pre-AndroCoV Trial.2020
16. Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males with mild-to-moderate COVID-19 (The Pre-AndroCoV Male Trial).2020
17. Multi-modular AI Approach to Streamline Autism Diagnosis in Young ChildrenScientific Reports · 2020
18. Automated data extraction and ensemble methods for predictive modeling of breast cancer outcomes after radiation therapyMedical Physics · 2018
19. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumoursBritish Journal of Cancer · 2016
20. Malignant Hyperthermia Deaths Related to Inadequate Temperature Monitoring, 2007–2012Anesthesia & Analgesia · 2014